Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q1

4544.TEDINET S100OZDP
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥65.3bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥272.9bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥63.5bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥8.6bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥12.2bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥8.5bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥47.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.9bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥8.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥11.4bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥5.6bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥8.3bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥5.6bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥8.3bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥278.3bnat 2022-06-30Cons.Assets
Total assets¥286.6bnat 2022-03-31Cons.Assets
Total assets¥250.2bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥132.3bnat 2022-06-30Cons.Liabilities
Total liabilities¥146.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥146.0bnat 2022-06-30Cons.Net assets
Net assets / equity¥140.2bnat 2022-03-31Cons.Net assets
Net assets / equity¥118.5bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥39.7bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥46.5bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥39.7bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥37.3bnat 2021-06-30Cons.Cash and cash equivalents
Cash & equivalents¥43.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.1bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Operating cash flow¥55.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.6bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7.3bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥30.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.4bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥21.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥8.0bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥98.252022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥519.552021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥146.32021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥98.242022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥519.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥146.232021-04-01 → 2021-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio52.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio48.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio47.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.5bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.5bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥607m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥43.4bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥43.4bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥27m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥18.5bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥15.0bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.5bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4m
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-06-30¥440m
—segment totalrevenue2022-04-01 → 2022-06-30¥68.8bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥65.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.5bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥9.2bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥502m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥41.7bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥41.7bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥14m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥6.7bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥16.4bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥14.4bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥5.3bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2021-04-01 → 2021-06-30¥7.4bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2021-04-01 → 2021-06-30¥7.4bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5m
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2021-04-01 → 2021-06-30¥821m
—segment totalrevenue2021-04-01 → 2021-06-30¥65.4bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥63.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥2.0bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥12.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 460
ItemContextValueUnit
Cash dividends paid fin cfPrior1YTDDuration-5268000000JPY
Cash dividends paid fin cfCurrentYTDDuration-3579000000JPY
Repayments of finance lease obligations fin cfPrior1YTDDuration-930000000JPY
Repayments of finance lease obligations fin cfCurrentYTDDuration-1052000000JPY
Other net fin cfPrior1YTDDuration-12000000JPY
Other net fin cfCurrentYTDDuration0JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-8023000000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-6442000000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration113000000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration887000000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration-5700000000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration-6752000000JPY
Cash and cash equivalentsPrior2YearInstant42950000000JPY
Cash and cash equivalentsPrior1YearInstant46479000000JPY
Increase in cash and cash equivalents from newly consolidated subsidiary ccePrior1YTDDuration0JPY
Increase in cash and cash equivalents from newly consolidated subsidiary cceCurrentYTDDuration－JPY
Cash and cash equivalentsPrior1QuarterInstant37250000000JPY
Cash and cash equivalentsCurrentQuarterInstant39727000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember41673000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember14448000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember7370000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember63492000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration63492000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember14000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember1932000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember5000000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember1952000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-1952000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember41688000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember16380000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember7375000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember65445000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-1952000000JPY
Net salesPrior1YTDDuration63492000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember6652000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember5255000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember821000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember12729000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-502000000JPY
Operating incomePrior1YTDDuration12227000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember43358000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember14978000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember6994000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember65331000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration65331000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember27000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember3476000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass